RB1 and eye neoplasm: Bilaterally affected individuals and 13%–15% of unilaterally affected individuals are expected to show an RB1 mutation in blood [6, 7]; the rest 85% of unilaterally affected patients were found not to carry either of their eye tumor RB1 mutations in blood; neither molecular testing nor clinical surveillance of siblings is required [8].